Use of recombinant factor VIIa in hereditary bleeding disorders.
Several doses of rFVIIa have been used, as well as bolus versus continuous infusion. Early use achieves a better outcome. However, there is no available routine laboratory test which can be used to monitor the use of rFVIIa, and cost remains an important limiting factor. Adverse events are very small in number, especially the occurrence of thrombotic events or antibody formation.
– M. Aldouri.